The small-molecule compound BM-1197 inhibits the antiapoptotic regulators Bcl-2/Bcl-xL and triggers apoptotic cell death in human colorectal cancer cells

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3447-3455

  Ye, Lijun ^a   Yuan, Gang ^a   Xu, Fei ^b   Sun, Yueli ^b   Chen, Ziyan ^a   Chen, Miaohong ^a   Li, Tianxiao ^a   Sun, Pingping ^a   Li, Shuxia ^a   Sun, Jian ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Apoptosis; Bcl 2; BH3 mimetic; BM 1197; Colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BIM PROTEIN; BM 1197; CASPASE 3; CYTOCHROME C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN INHIBITOR; PUMA PROTEIN; UNCLASSIFIED DRUG; ANILINE DERIVATIVE; BM-1197; PROTEIN BCL X; SULFONAMIDE;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G1 PHASE; COLORECTAL CANCER; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG EFFECTS; METABOLISM; PATHOLOGY; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; SECRETION (PROCESS); TUMOR CELL LINE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CASPASE 3; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; CYTOCHROMES C; HUMANS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS C-BCL-2; SULFONAMIDES;

EID: 84929950305     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2980-z     Document Type: Article

References (33)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
2. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383:1490–502.
3. Dai Z, Zheng RS, Zou XN, Zhang SW, Zeng HM, Li N, et al. Analysis and prediction of colorectal cancer incidence trend in China. Zhonghua Yu Fang Yi Xue Za Zhi. 2012;46:598–603.
4. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014;64:104–17.
5. Marin JJ, Sanchez de Medina F, Castano B, Bujanda L, Romero MR, Martinez-Augustin O, et al. Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metab Rev. 2012;44:148–72.
6. Crea F, Nobili S, Paolicchi E, Perrone G, Napoli C, Landini I, et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug Resist Update. 2011;14:280–96.
7. Tsai HL, Chu KS, Huang YH, Su YC, Wu JY, Kuo CH, et al. Predictive factors of earlyrelapse in UICC stage I-III colorectal cancer patients after curative resection. J Surg Oncol. 2009;100:736–43.
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
9. Billard C. BH3 mimetics: status of the field and new developments. Mol Cancer Ther. 2013;12:1691–700.
10. Ren D, Tu HC, Kim H, Wang GX, Bean GR, Tkeuchi O, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science. 2010;330:1390–3.
11. Huang DC, Strasser A. BH3-only proteins—essential initiators of apoptotic cell death. Cell. 2010;103:839–42.
12. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26:1324–37.
13. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell. 2005;17:525–35.
14. Jin-Song Y, Zhao-Xia W, Cheng-Yu L, Xiao-Di L, Ming S, Yuan-Yuan G, et al. Prognostic significance of Bcl-xL gene expression in human colorectal cancer. Acta Histochem. 2011;113:810–4.
15. Maurer CA, Friess H, Buhler SS, Wahl BR, Graber H, Zimmermann A, et al. Apoptosis inhibiting factor Bcl-xL might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig Dis Sci. 1998;43:2641–8.
16. Hosseini A, Espona-Fiedler M, Soto-Cerrato V, Quesada R, Perez-Tomas R, Guallar V. Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family members. PLoS One. 2013;8:e57562.
17. Suzuki M, Youle RJ, Tjandra N. Structure of Bax: coregulation of dimer formation and intracellular localization. Cell. 2000;103:645–54.
18. Gallenne T, Gautier F, Oliver L, Hervouet E, Noël B, Hickman JA, et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol. 2009;85:279–90.
19. Merino D, Khaw SL, Glaser SP, Anderson DJ, Belmont LD, Wong LD, et al. Bcl-2, Bcl-x(L), and Bcl-w are not equivalent targets of ABT-737and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood. 2012;119:5807–16.
20. Rudin CM, Hann CL, Garon EB, Ribeiro de Oliveira M, Bonomi PD, Camidge DR, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012;18:3163–9.
21. Hann CL, Daniel VC, Sugar EA, Daniel VC, Sugar EA, Dobromilskaya I, et al. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer. Cancer Res. 2008;68:2321–8.
22. Wang C, Youle RJ. Predominant requirement of Bax for apoptosis in HCT116 cells is determined by Mcl-1’s inhibitory effect on Bak. Oncogene. 2012;31:3177–89.
23. Bai L, Chen J, McEachern D, Liu L, Zhou H, Aguilar A, et al. BM-1197: a novel and specific Bcl-2/Bcl-xL inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS One. 2014;9:e99404.
24. Hu ZY, Zhu XF, Zhong ZD, Sun J, Wang J, Yang D, et al. ApoG2, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces apoptosis and suppresses tumor growth in nasopharyngeal carcinoma xenografts. Int J Cancer. 2008;123:2418–29.
25. Kontos CK, Christodoulou MI, Scorilas A. Apoptosis-related BCL2-family members. Key players in chemotherapy. Anticancer Agents Med Chem. 2014;14:353–74.
26. Violette S, Poulain L, Dussaulx E, Poulain L, Dussaulx E, Pepin D, et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer. 2002;98:498–504.
27. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res. 2008;14:8132–42.
28. Lustosa SA, Logullo A, Artigiani R, Saad SS, Goldenberg A, Matos D. Analysis of the correlation between p53 and bcl-2 expression with staging and prognosis of the colorectal adenocarcinoma. Acta Cir Bras. 2005;20:353–7.
29. Menezes HL, Juca MJ, Gomes EG, Nunes BL, Costa HO, Matos D. Analysis of the immunohistochemical expressions of p53, bcl-2 and Ki-67 in colorectal adenocarcinoma and their correlations with the prognostic factors. Arq Gastroenterol. 2010;47:141–7.
30. Rooswinkel RW, van de Kooij B, Verheij M, Borst J. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B. Cell Death Dis. 2012;3:e366.
31. Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, Shore P, et al. Gene structure alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mamm Genome. 2001;12:163–8.
32. Weber A, Paschen SA, Heger K, Wilfling F, Frankenberg T, Bauerschmitt H, et al. BimS-induced apoptosis requires mitochondrial localization but not interaction with anti-apoptotic Bcl-2 proteins. J Cell Biol. 2007;177:625–36.
33. Marani M, Tenev T, Hancock D, Downward J, Lemoine NR. Identification of novel isoforms of the BH3 domain protein Bim which directly activate Bax to trigger apoptosis. Mol Cell Biol. 2002;22:3577–89.